Floatz logo

dt2216

Ovarian Carcinoma

Elizabeth Stover, MD, PhDSmall moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

244 Active assets in the Ovarian Carcinoma cohort.

Asset / SponsorPhaseRating
Trabectedin
AGO Research GmbH
Phase 4BBB
Mirvetuximab Soravtansine
AstraZeneca
Phase 3BBB
Olaparib
Imunon
Phase 4BB
Irinotecan
OHSU Knight Cancer Institute
Phase 2BB
Carboplatin
University of Washington
Phase 3BB

View all 50 →

Same molecule, other indications

dt2216 is also rated in:

fibrolamellar hepatocellular carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
Recurrent Childhood Malignant Solid NeoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
Refractory Childhood Malignant Solid NeoplasmDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →